Netarsudil mesylate

Netarsudil mesylate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated in open-angle glaucoma and ocular hypertension. Its therapeutic use is listed as ophthalmic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Netarsudil dimesylate and Netarsudil mesilate. Its PubChem CID is 90410375.

CAS No 1422144-42-0
Molecular Formula C30H35N3O9S2
Molecular Weight 645.7 g/mol
Synonyms [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;methanesulfonic acid

Frequently Asked Questions